Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Browse by Current Cardiff authors

Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Number of items: 48.

Salisbury, Richard A., Curto-Garcia, Natalia, O'Sullivan, Jennifer, Chen, Frederick, Polzella, Paolo, Godfrey, Anna L., Russell, James, Knapper, Steven, Willan, John, Frewin, Rebecca, Joshi, Shivani, Arami, Siamak, Burns, Sarah, Teh, Chun Huat, Wadelin, Frances, Dhanapal, Jaymathi, Neelakantan, Pratap, Milojkovic, Dragana, Psaila, Beth, Szydlo, Richard, Francis, Sebastian, Cargo, Catherine, Jain, Manish, McGregor, Andrew, Wallis, Louise, Duncombe, Andrew, Hussein, Hayder, Dyer, Peter, Munro, Laura, Bond, Lee, McMullin, Mary Frances, Somervaille, Tim C. P., Garg, Mamta, Sekhar, Mallika, Harrison, Claire, Mead, Adam J. and Innes, Andrew J. 2021. Results of a national UK physician reported survey of COVID-19 infection in patients with a myeloproliferative neoplasm. Leukemia 35 , pp. 2424-2430. 10.1038/s41375-021-01143-2

Rastogi, Namrata, Baker, Sarah, Man, Stephen, Uger, Robert A., Wong, Mark, Coles, Steve J., Hodges, Marie, Gilkes, Amanda, Knapper, Steven, Darley, Richard and Tonks, Alex 2021. Use of an anti-CD200 blocking antibody improves immune responses to AML in vitro and in vivo. British Journal of Haematology 193 (1) , pp. 155-159. 10.1111/bjh.17125

Burnett, Alan K., Russell, Nigel H., Hills, Robert K., Knapper, Stephen, Freeman, Sylvie, Huntly, Brian, Clark, Richard E., Thomas, Ian F., Kjeldsen, Lars, McMullin, Mary Frances, Drummond, Mark, Kell, Jonathan and Spearing, Ruth 2021. Defining the optimal total number of chemotherapy courses in younger patients with acute myeloid leukemia: a comparison of three versus four courses. Journal of Clinical Oncology 39 (8) , pp. 890-901. 10.1200/JCO.20.01170

Montesinos, Pau, Roboz, Gail J., Bulabois, Claude-Eric, Subklewe, Marion, Platzbecker, Uwe, Ofran, Yishai, Papayannidis, Cristina, Wierzbowska, Agnieszka, Shin, Ho Jin, Doronin, Vadim, Deneberg, Stefan, Yeh, Su-Peng, Ozcan, Mehmet Ali, Knapper, Steven, Cortes, Jorge, Pollyea, Daniel A., Ossenkoppele, Gert, Giralt, Sergio, Döhner, Hartmut, Heuser, Michael, Xiu, Liang, Singh, Indrajeet, Huang, Fei, Larsen, Julie S. and Wei, Andrew H. 2021. Safety and efficacy of talacotuzumab plus decitabine or decitabine alone in patients with acute myeloid leukemia not eligible for chemotherapy: results from a multicenter, randomized, phase 2/3 study. Leukemia 35 (1) , 62–74. 10.1038/s41375-020-0773-5

Peterlin, Pierre, Chevallier, Patrice, Knapper, Steven and Collin, Matthew 2021. FLT3 ligand in acute myeloid leukemia: a simple test with deep implications. Leukemia & Lymphoma 62 (2) , pp. 264-270. 10.1080/10428194.2020.1834091
Item availability restricted.

Zabkiewicz, Joanna, Lazenby, Michelle, Edwards, Gareth, Bygrave, Ceri A., Omidvar, Nader, Zhuang, Lihui, Knapper, Steve, Guy, Carol, Hills, Robert K., Burnett, Alan K. and Alvares, Caroline L. 2020. Combination of a mitogen‐activated protein kinase inhibitor with the tyrosine kinase inhibitor pacritinib combats cell adhesion‐based residual disease and prevents re‐expansion of FLT3 ‐ITD acute myeloid leukaemia. British Journal of Haematology 191 (2) , pp. 231-242. 10.1111/bjh.16665

Alanazi, Bader, Munje, Chinmay R., Rastogi, Namrata, Williamson, Andrew J. K., Taylor, Samuel, Hole, Paul S., Hodges, Marie, Doyle, Michelle, Baker, Sarah, Gilkes, Amanda F., Knapper, Steven, Pierce, Andrew, Whetton, Anthony D., Darley, Richard L. and Tonks, Alex 2020. Integrated nuclear proteomics and transcriptomics identifies S100A4 as a therapeutic target in acute myeloid leukemia. Leukemia 34 (2) , pp. 427-440. 10.1038/s41375-019-0596-4

Milne, Paul, Wilhelm-Benartzi, Charlotte, Grunwald, Michael R., Bigley, Venetia, Dillon, Richard, Freeman, Sylvie D., Gallagher, Kathleen, Publicover, Amy, Pagan, Sarah, Marr, Helen, Jones, Gail L., Dickinson, Anne M., Grech, Angela, Burnett, Alan K., Russell, Nigel H., Levis, Mark, Knapper, Steven and Collin, Matthew 2019. Serum Flt3 ligand is a biomarker of progenitor cell mass and prognosis in acute myeloid leukemia. Blood Advances 3 (20) , pp. 3052-3061. 10.1182/bloodadvances.2019000197

Legge, Sophie E., Pardinas, Antonio F., Helthuis, Marinka, Jansen, John A., Jollie, Karel, Knapper, Steven, MacCabe, James H., Rujescu, Dan, Collier, David A., O'Donovan, Michael C., Owen, Michael J. and Walters, James T. R. 2019. A genome-wide association study in individuals of African ancestry reveals the importance of the Duffy-null genotype in the assessment of clozapine-related neutropenia. Molecular Psychiatry 24 , pp. 328-337. 10.1038/s41380-018-0335-7

McMullin, M. F., Harrison, C. N., Ali, S., Cargo, C., Chen, F., Ewing, J, Garg, M., Godfrey, A., Knapper, Steven, McLorcan, D., Nangalia, J., Sekhar, M., Wadelin, F. and Mead, A. J. 2019. A guideline for the diagnosis and management of polycythaemia vera. British Journal of Haematology 184 (2) , pp. 176-191. 10.1111/bjh.15648

Burnett, Alan K, Das Gupta, Emma, Knapper, Steve, Khwaja, Asim, Sweeney, Marion, Kjeldsen, Lars, Hawkins, Timothy, Betteridge, Sophie E., Cahalin, Paul, Clark, Richard E., Hills, Robert K. and Russell, Nigel H. 2018. Addition of the mammalian target of rapamycin inhibitor, Everolimus, to consolidation therapy in acute myeloid leukaemia: experience from the UK NCRI AML17 trial. Haematologica 103 (10) , pp. 1654-1661. 10.3324/haematol.2018.189514

Harrison, Claire N., Mead, Adam J., Panchal, Anesh, Fox, Sonia, Yap, Christina, Gbandi, Emmanouela, Houlton, Aimee, Alimam, Samah, Ewing, Joanne, Wood, Marion, Chen, Frederick, Coppell, Jason, Panoskaltsis, Nicki, Knapper, Steven, Ali, Sahra, Hamblin, Angela, Scherber, Robyn, Dueck, Amylou C., Cross, Nicholas C. P., Mesa, Ruben and McMullin, Mary Frances 2017. Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide. Blood 130 (17) , pp. 1889-1897. 10.1182/blood-2017-05-785790

Williams, Jenna, Heppel, Nicole, Britt-Compton, Bethan, Grimstead, Julia, Robinson, Rhiannon, Tauro, Sudhir, Bowen, David, Knapper, Steven, Groves, Michael, Hills, Robert, Pepper, Christopher J., Baird, Duncan M. and Fegan, Christopher D. 2017. Telomere length is an independent prognostic marker in MDS but not in de novo AML. British Journal of Haematology 178 (2) , pp. 240-249.

Khan, N., Hills, R. K., Virgo, P., Couzens, S., Clark, N., Gilkes, A., Richardson, P., Knapper, S., Grimwade, D., Russell, N. H., Burnett, A. K. and Freeman, S. D. 2017. Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia. Leukemia 31 , pp. 1059-1068. 10.1038/leu.2016.309

Knapper, Steven, Russell, Nigel, Gilkes, Amanda, Hills, Robert K., Gale, Rosemary E., Cavenagh, James D., Jones, Gail, Kjeldsen, Lars, Grunwald, Michael R., Thomas, Ian, Konig, Heiko, Levis, Mark J. and Burnett, Alan K. 2017. A randomized assessment of adding the kinase inhibitor lestaurtinib to first-line chemotherapy for FLT3-mutated AML. Blood 129 (9) , pp. 1143-1154. 10.1182/blood-2016-07-730648

Butt, Nauman M., Lambert, Jonathan, Ali, Sahra, Beer, Philip A., Cross, Nicholas C. P., Duncombe, Andrew, Ewing, Joanne, Harrison, Claire N., Knapper, Steven, McLornan, Donal, Mead, Adam J., Radia, Deepti and Bain, Barbara J. 2017. Guideline for the investigation and management of eosinophilia. British Journal of Haematology 176 (4) , pp. 553-572. 10.1111/bjh.14488

Khan, Naeem, Hills, Robert, Knapper, Steven, Steadman, Lora, Qureshi, Ushna, Rector, Jerrold L., Bradbury, Charlotte, Russell, Nigel H., Vyas, Paresh, Burnett, Alan K., Grimwade, David, Hole, Paul and Freeman, Sylvie D. 2016. Normal hematopoietic progenitor subsets have distinct reactive oxygen species, BCl2 and cell-cycle profiles that are decoupled from maturation in acute myeloid leukemia. PLOS ONE 11 (9) , e0163291. 10.1371/journal.pone.0163291

Beauverd, Yan, Radia, Deepti, Cargo, Catherine, Knapper, Steve, Drummond, Mark, Pillai, Arvind, Harrison, Claire and Robinson, Susan 2016. Pegylated interferon alpha-2a for essential thrombocythemia during pregnancy: outcome and safety. A case series. Haematologica 101 (5) , e182-e184. 10.3324/haematol.2015.139691

Zabkiewicz, Joanna, Gilmour, Marie, Hills, Robert, Vyas, Pares, Bone, Elizabeth, Davidson, Alan, Burnett, Alan and Knapper, Steven 2016. The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaemias. Oncotarget 7 (13) , pp. 16650-16662. 10.18632/oncotarget.7692

Burnett, Alan K., Russell, Nigel H., Hills, Robert K., Bowen, David, Kell, Jonathan, Knapper, Steve, Morgan, Yvonne G., Lok, Jennie, Grech, Angela, Jones, Gail, Khwaja, Asim, Friis, Lone, McMullin, Mary Frances, Hunter, Ann, Clark, Richard E. and Grimwade, David 2015. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial. Lancet Oncology 16 (13) , pp. 1295-1305. 10.1016/S1470-2045(15)00193-X

Coles, S. J., Gilmour, M. N., Reid, R., Knapper, S., Burnett, A. K., Man, S., Tonks, A. and Darley, R. L. 2015. The immunosuppressive ligands PD-L1 and CD200 are linked in AML T-cell immunosuppression: identification of a new immunotherapeutic synapse. Leukemia 29 , pp. 1952-1954. 10.1038/leu.2015.62

Knapper, Steven 2015. The FLAM regimen: revisiting time sequential induction therapy for patients with poor-risk acute myeloid leukemia. Haematologica 100 (9) , pp. 1105-1107. 10.3324/haematol.2015.134023

Mead, Adam J., Milojkovic, Dragana, Knapper, Steven, Garg, Mamta, Chacko, Joseph, Farquharson, Mira, Yin, John, Ali, Sahra, Clark, Richard E., Andrews, Chris, Dawson, Meryem Ktiouet and Harrison, Claire 2015. Response to ruxolitinib in patients with intermediate-1-, intermediate-2-, and high-risk myelofibrosis: results of the UK ROBUST Trial. British Journal of Haematology 170 (1) , pp. 29-39. 10.1111/bjh.13379

Reilly, John T., McMullin, Mary Frances, Beer, Philip A., Butt, Nauman, Conneally, Eibhlin, Duncombe, Andrew S., Green, Anthony R., Mikhaeel, George, Gilleece, Marie H., Knapper, Steven, Mead, Adam J., Mesa, Ruben A., Sekhar, Mallika and Harrison, Claire N. 2014. Use of JAK inhibitors in the management of myelofibrosis: a revision of the British Committee for Standards in Haematology Guidelines for Investigation and Management of Myelofibrosis 2012. British Journal of Haematology 167 (3) , pp. 418-420. 10.1111/bjh.12985

Andersen, Christen Lykkegaard, Bjørn, Mads Emil, McMullin, Mary Frances, Harrison, Claire, Samuelsson, Jan, Ejerblad, Elisabeth, Zweegman, Sonja, Fernandes, Savio, Bareford, David, Knapper, Steven, Löfvenberg, Eva, Linder, Olle, Andreasson, Bjørn, Ahlstrand, Erik, Jensen, Morten Krogh, Bjerrum, Ole Weis, Vestergaard, Hanne, Larsen, Herdis, Klausen, Tobias Wirenfeldt, Mourits-Andersen, Torben, Skov, Vibe, Thomassen, Mads, Kruse, Torben, Grønbæk, Kirsten and Hasselbalch, Hans Carl 2014. Circulating YKL-40 in patients with essential thrombocythemia and polycythemia vera treated with the novel histone deacetylase inhibitor vorinostat. Leukemia Research 38 (7) , pp. 816-821. 10.1016/j.leukres.2014.04.002

Knapper, Steven, Chevassut, Timothy, Duarte, Rafael, Bergua, Juan Miguel, Salamero, Olga, Johansen, Malin, Jacobsen, Tove Flem, Hals, Petter-Arnt, Rasch, Wenche, Gianella-Borradori, Athos and Smith, Matthew 2014. Elacytarabine in relapsed/refractory acute myeloid leukaemia: an evaluation of clinical efficacy, pharmacokinetics, cardiac safety and effects on lipid profile. Leukemia Research 38 (3) , pp. 346-351. 10.1016/j.leukres.2013.12.011

Burnett, Alan Kenneth, Russell, N. H., Hunter, A. E., Milligan, D., Knapper, Steven, Wheatley, K., Yin, J., McMullin, M. F., Ali, S., Bowen, D. and Hills, Robert Kerrin 2013. Clofarabine doubles the response rate in older patients with acute myeloid leukemia but does not improve survival. Blood 122 (8) , pp. 1384-1394. 10.1182/blood-2013-04-496596

Moore, A. S., Kearns, P. R., Knapper, Steven, Pearson, A. D. J. and Zwaan, C. M. 2013. Novel therapies for children with acute myeloid leukaemia. Leukemia 27 (7) , pp. 1451-1460. 10.1038/leu.2013.106

Andersen, Christen L., McMullin, Mary F., Ejerblad, Elisabeth, Zweegman, Sonja, Harrison, Claire, Fernandes, Savio, Bareford, David, Knapper, Steven, Samuelsson, Jan, Löfvenberg, Eva, Linder, Olle, Andreasson, Bjørn, Ahlstrand, Erik, Jensen, Morten K., Bjerrum, Ole W., Vestergaard, Hanne, Larsen, Herdis, Klausen, Tobias W., Mourits-Andersen, Torben and Hasselbalch, Hans C. 2013. A phase II study of vorinostat (MK-0683) in patients with polycythaemia vera and essential thrombocythaemia. British Journal of Haematology 162 (4) , pp. 498-508. 10.1111/bjh.12416

Craddock, C., Quek, L., Goardon, N., Freeman, S., Siddique, S., Raghavan, M., Aztberger, A., Schuh, A., Grimwade, D., Ivey, A., Virgo, P., Hills, Robert Kerrin, McSkeane, T., Arrazi, J., Knapper, Steven, Brookes, C., Davies, B., Price, A., Wall, K., Griffiths, M., Cavenagh, J., Majeti, R., Weissman, I., Burnett, Alan Kenneth and Vyas, P. 2013. Azacitidine fails to eradicate leukemic stem/progenitor cell populations in patients with acute myeloid leukemia and myelodysplasia. Leukemia 27 (5) , pp. 1028-1036. 10.1038/leu.2012.312

Walsby, Elisabeth Jane, Lazenby, Michelle, Pepper, Christopher John, Knapper, Steven and Burnett, Alan Kenneth 2013. The HSP90 inhibitor NVP-AUY922-AG inhibits the PI3K and IKK signalling pathways and synergizes with cytarabine in acute myeloid leukaemia cells. British Journal of Haematology 161 (1) , pp. 57-67. 10.1111/bjh.12215

Reilly, John T., McMullin, Mary Frances, Beer, Philip A., Butt, Nauman, Conneally, Eibhlean, Duncombe, Andrew, Green, Anthony R., Michaeel, N. George, Gilleece, Marie H., Hall, Georgina W., Knapper, Steven, Mead, Adam, Mesa, Ruben A., Sekhar, Mallika, Wilkins, Bridget and Harrison, Claire N. 2012. Guideline for the diagnosis and management of myelofibrosis. British Journal of Haematology 158 (4) , pp. 453-471. 10.1111/j.1365-2141.2012.09179.x

Taylor, Philip Russel, Heydeck, Dagmar, Jones, Gareth Wyn, Kronke, Gerhard, Funk, Colin D., Knapper, Steven, Adams, Deborah, Kuhn, Hartmut and O'Donnell, Valerie Bridget 2012. Development of myeloproliferative disease in 12/15-lipoxygenase deficiency [Letter]. Blood 119 (25) , pp. 6173-6174. 10.1182/blood-2012-02-410928

Knapper, Steven, White, Paul Charles, Levis, Mark J., Hills, Robert Kerrin, Russell, Nigel H. and Burnett, Alan Kenneth 2011. The efficacy of the FLT3 inhibitor Lestaurtinib in AML depends on adequate plasma inhibitory activity (PIA), and is unaffected by rising FLT ligand levels: an update of the NCRI AML15 & 17 trials. Blood -New York- 118 (21) , p. 194.

Szegezdi, Eva, Reis, Carlos R., Sloot, Almer M. van der, Natoni, Alessandro, O'Reilly, Aoife, Reeve, Janice, Cool, Robbert H., O'Dwyer, Michael, Knapper, Steven, Serrano, Luis, Quax, Wim J. and Samali, Afshin 2011. Targeting AML through DR4 with a novel variant of rhTRAIL. Journal of Cellular and Molecular Medicine 15 (10) , pp. 2216-2231. 10.1111/j.1582-4934.2010.01211.x

Sato, Takashi, Yang, Xiaochuan, Knapper, Steven, White, Paul Charles, Smith, B. Douglas, Galkin, Steven, Small, Donald, Burnett, Alan Kenneth and Levis, Mark 2011. FLT3 ligand impedes the efficacy of FLT3 inhibitors in vitro and in vivo. Blood 117 (12) , pp. 3286-3293. 10.1182/blood-2010-01-266742

Walsby, Elisabeth Jane, Coles, Steven, Knapper, Steven and Burnett, Alan Kenneth 2011. The topoisomerase II inhibitor voreloxin causes cell cycle arrest and apoptosis in myeloid leukemia cells and acts in synergy with cytarabine. Haematologica 96 (3) , pp. 393-399. 10.3324/haematol.2010.032680

Goardon, Nicolas, Marchi, Emanuele, Atzberger, Ann, Quek, Lynn, Schuh, Anna, Soneji, Shamit, Woll, Petter, Mead, Adam, Alford, Kate A., Rout, Raj, Chaudhury, Salma, Gilkes, Amanda F., Knapper, Steven, Beldjord, Kheira, Begum, Suriya, Rose, Susan, Geddes, Nicola, Griffiths, Mike, Standen, Graham, Sternberg, Alexander, Cavenagh, Jamie, Hunter, Hannah, Bowen, David, Killick, Sally, Robinson, Lisa, Price, Andrew, Macintyre, Elizabeth, Virgo, Paul, Burnett, Alan Kenneth, Craddock, Charles, Enver, Tariq, Jacobsen, Sten Eirik W., Porcher, Catherine and Vyas, Paresh 2011. Coexistence Of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. Cancer Cell 19 (1) , pp. 138-152. 10.1016/j.ccr.2010.12.012

Moore, Catherine, Galiano, Monica, Lackenby, Angie, Abdelrahman, Tamer, Barnes, Rosemary Ann, Evans, Meirion Rhys, Fegan, Christopher, Froude, Susannah, Hastings, Mark, Knapper, Steven, Litt, Emma, Price, Nicola, Salmon, Roland, Temple, Mark and Davies, Eleri 2011. Evidence of person-to-person transmission of oseltamivir-resistant pandemic influenza A(H1N1) 2009 virus in a hematology unit. International Journal of Infectious Diseases 203 (1) , pp. 18-24. 10.1093/infdis/jiq007

Knapper, Steven 2011. The clinical development of FLT3 inhibitors in acute myeloid leukemia. Expert Opinion on Investigational Drugs 20 (10) , pp. 1377-1395. 10.1517/13543784.2011.611802

Dijk, Marianne van, Murphy, Eoin, Morrell, Ruth, Knapper, Steven, O'Dwyer, Michael, Samali, Afshin and Szegezdi, Eva 2011. The proteasome inhibitor bortezomib sensitizes AML with myelomonocytic differentiation to TRAIL mediated apoptosis. Cancers 3 (4) , pp. 1329-1350. 10.3390/cancers3011329

Knapper, Steven, Burnett, Alan Kenneth, Hills, Robert Kerrin, Small, Donald and Levis, Mark 2009. Lestaurtinib FLT3 inhibitory activity is modulated by concomitant azole therapy and may Influence relapse risk. Blood -New York- 114 (22) , p. 326.

Burnett, Alan Kenneth and Knapper, Steven 2009. Acute myeloid leukaemia. In: Treleaven, Jennifer G. and Barrett, A. John eds. Hematopoietic Stem Cell Transplantation in Clinical Practice, Edinburgh: Churchill Livingstone Elsevier, pp. 25-34.

Hewamana, Saman, Pepper, Christopher John, Couzens, Stephen, Thomas, Alun and Knapper, Steven 2008. IgM multiple myeloma: a diagnostic challenge in a patient with coexisting chronic lymphocytic leukaemia. International Journal of Hematology 88 (4) , pp. 424-427. 10.1007/s12185-008-0179-z

Knapper, Steven 2007. FLT3 inhibition in acute myeloid leukaemia. British Journal of Haematology 138 (6) , pp. 687-699. 10.1111/j.1365-2141.2007.06700.x

Burnett, Alan Kenneth and Knapper, Steven 2007. Targeting treatment in AML. Hematology: American Society of Haematology Education Program Book 2007 (1) , pp. 429-434. 10.1182/asheducation-2007.1.429

Knapper, Steven, Burnett, Alan K., Littlewood, Tim, Kell, William Jonathan, Agrawal, Sam, Chopra, Raj, Clark, Richard, Levis, Mark J. and Small, Donald 2006. A phase 2 trial of the FLT3 inhibitor lestaurtinib (CEP701) as first-line treatment for older patients with acute myeloid leukemia not considered fit for intensive chemotherapy. Blood 108 (10) , pp. 3262-3270. 10.1182/blood-2006-04-015560

Knapper, Steven, Mills, Kenneth I., Gilkes, Amanda F., Austin, Steve J., Walsh, Valerie and Burnett, Alan K. 2006. The effects of lestaurtinib (CEP701) and PKC412 on primary AML blasts: the induction of cytotoxicity varies with dependence on FLT3 signaling in both FLT3-mutated and wild-type cases. Blood 108 (10) , pp. 3494-3503. 10.1182/blood-2006-04-015487

This list was generated on Fri Sep 17 04:22:40 2021 BST.